Biotech Values

[poorgradstudent]

ARRY:

Thanks for the pointer. Data look ok to me (if we disregard the drug switch), but as you say I would have liked that additional sweetener for the phase 3 to tilt the scales towards the MEK inhibitor. And perhaps an SPA would have been nice, although those seem to be falling a little out of favour lately.

And please somebody tell me they didn't spend time and money making that uterus / fallopian tube-looking tulip art for the MILO trial...

Edit: And as you say, i really really don't understand how you move into a phase 3 with one drug based on clinical data accrued using another drug. Even if they target the same signaling pathway.